What is iCliniq Tes for Prostate Cancer?
iCliniq Tes is your AI-powered prostate cancer companion, crafted by expert oncologists. From personalized insights to real-time guidance, it empowers you to make informed decisions and control your care. Navigate treatment with confidence, Tes has your back!
Problem
Prostate cancer patients rely on periodic consultations with oncologists for guidance, leading to delays in receiving personalized insights and real-time support between appointments.
Solution
AI-powered healthcare platform where users input medical data to receive personalized prostate cancer insights and real-time guidance from expert oncologists, e.g., treatment options, symptom analysis, and care navigation.
Customers
Prostate cancer patients, oncologists, and caregivers seeking immediate, expert-backed medical support.
Unique Features
Combines AI analysis with human oncologist validation for accuracy, offers 24/7 access to tailored treatment recommendations, and integrates patient history for contextualized care plans.
User Comments
Saves time during critical health decisions
Reduces anxiety with reliable information
Easy to use for non-tech-savvy patients
Complements doctor consultations effectively
Empowers patients to track progress independently
Traction
Launched in 2024; exact user/revenue data unavailable publicly. Parent company iCliniq serves 5M+ patients globally with 10K+ doctors, suggesting scalability.
Market Size
Global prostate cancer treatment market valued at $5.1 billion in 2023, projected to reach $8.9 billion by 2030 (Grand View Research).
